Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5668664 | 0.89 | TK1 (0.39) | TK1TK2 | |
| SCHEMBL8539644 | 0.86 | LMNA (0.37) | TK2 | |
| SCHEMBL9030188 | 0.83 | P2RY2 (0.41) | — | |
| SCHEMBL9029503 | 0.83 | P2RY2 (0.41) | — | |
| SCHEMBL7192452 | 0.83 | TK2 (0.35) | TK1TK2 | |
| SCHEMBL6468417 | 0.76 | PNP (0.41) | TK1 | |
| SCHEMBL8004041 | 0.76 | LMNA (0.42) | — | |
| SCHEMBL9545108 | 0.74 | TK2 (0.40) | TK1TK2 | |
| SCHEMBL27271553 | 0.74 | TK2 (0.40) | TK1TK2 | |
| SCHEMBL4949384 | 0.74 | TK2 (0.39) | TK1TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1465905-A2 | ANTISENSE MODULATION OF MYD88 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2004-10-13 | — | — | EP | disclosed |
| EP-1328536-A1 | ANTISENSE MODULATION OF GLIOMA-ASSOCIATED ONCOGENE-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-07-23 | — | — | EP | disclosed |
| WO-2003049691-A2 | ANTISENSE MODULATION OF PCTAIRE PROTEIN KINASE 1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003046132-A2 | ANTISENSE MODULATION OF MYD88 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-06-05 | — | — | WO | disclosed |
| WO-2002020549-A1 | ANTISENSE MODULATION OF GLIOMA-ASSOCIATED ONCOGENE-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |